amlodipine vs glecaprevir/pibrentasvir
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of amlodipine and glecaprevir/pibrentasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
7.5 Drugs with No Observed Clinically Significant Interactions with MAVYRET No dose adjustment is required when MAVYRET is coadministered with the following medications: abacavir, amlodipine, caffeine, dextromethorphan, dolutegravir, elvitegravir/ cobicistat, emtricitabine, ethinyl estradiol of 20 mcg or less, felodipine, lamivudine, lamotrigine, losartan, midazolam, norethindrone or other progestin-only contraceptives, omeprazole, raltegravir, rilpivirine, sofosbuvir, tacrolimus, tenofovir alafenamide, tenofovir disoproxil fumarate, tolbutamide, and valsartan.
Norvasc
Mavyret
Amlodipine (Norvasc) is a drug that lowers blood pressure and treats chest pain. It belongs to a class of drugs called calcium channel blockers.
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
This medicine treats high blood pressure (hypertension). Lowering blood pressure reduces the risk of strokes and heart attacks. Amlodipine also treats chest pain (angina) caused by coronary artery disease, including chronic stable angina and vasospastic angina.
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.
Amlodipine blocks calcium from entering heart and blood vessel cells. This relaxes and widens blood vessels, making it easier for blood to flow. As a result, the heart does not have to work as hard, which lowers blood pressure and reduces chest pain.
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
- • Swelling in your ankles or feet
- • Dizziness
- • Flushing (redness of the face)
- • Palpitations (feeling your heart beat rapidly or irregularly)
- • Fatigue (feeling tired)
- • Headache
- • Feeling tired
- • Nausea
- Fatigue 15,697
- Diarrhoea 14,039
- Nausea 13,425
- Dyspnoea 13,218
- Dizziness 10,671
- Feeling tired 2,561
- Headache 2,203
- Nausea 1,125
- Itching 653
- Diarrhea 477
Amlodipine may cause low blood pressure, especially if you have severe aortic stenosis. Some people with severe heart disease may experience worsening chest pain or a heart attack when starting or increasing the dose of amlodipine. If you have severe liver problems, your doctor will increase your dose slowly.
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
Tell your doctor if you are pregnant or plan to become pregnant. High blood pressure during pregnancy can harm both the mother and the baby. Amlodipine passes into breast milk, but no harmful effects on the breastfed infant have been seen.
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
Also Compare, Nearby Drugs
Compare amlodipine with
How to Read This amlodipine vs glecaprevir/pibrentasvir Comparison
amlodipine is classified in the Calcium Channel Blocker drug class, while glecaprevir/pibrentasvir sits within the NS3/4A/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, amlodipine has 67,050 submissions while glecaprevir/pibrentasvir has 7,019. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to these two drugs do not significantly change how the other drug works or stays in your body.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for amlodipine or glecaprevir/pibrentasvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.